Preventive hepatitis C vaccine goes to midstage trial
Okairos initiated a midstage trial of a gene-based preventive vaccine against hepatitis C using NIH funding. While most vaccines prompt an antibody response, Okairos' vaccine is designed to stimulate T cells, which help the body combat disease. Bloomberg
Source: AABBsmartbrief

Press Release